Log inSign up
AAOIFI No. 21 screening

Is ACRS halal?

Aclaris Therapeutics, Inc.

Not halal

Aclaris Therapeutics, Inc. did not pass AAOIFI screening. The failed check is shown below.

Checked: 15 October 2026

Exchange

NASDAQ

Price

3.28

Day

-6.02%

Market cap

$506.4M

Industry

Biotechnology

Sector

Healthcare

What the company does

Aclaris Therapeutics is a clinical-stage biotech developing drugs for immuno-inflammatory diseases (bosakatug for atopic dermatitis, ATI-2138 for alopecia). Its money so far comes from partnership/licensing payments.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $240.98M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $170.62M ÷ 36-month average market cap $240.98M = 70.8%

    70.8%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    Interest income $7.64M ÷ annual revenue $7.83M (2025) = 97.6%

    97.6%

    Fail

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $506.36M.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyACRS's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →